Parallel Advisors LLC Has $333,000 Holdings in GSK plc (NYSE:GSK)

Parallel Advisors LLC boosted its stake in GSK plc (NYSE:GSK) by 20.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,840 shares of the pharmaceutical company’s stock after purchasing an additional 1,690 shares during the period. Parallel Advisors LLC’s holdings in GSK were worth $333,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. FMR LLC raised its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC raised its holdings in GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares during the last quarter. Mondrian Investment Partners LTD lifted its position in shares of GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after purchasing an additional 874,004 shares during the period. Equity Investment Corp boosted its stake in shares of GSK by 13.3% in the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after purchasing an additional 466,327 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its position in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $39.22 on Friday. The business has a 50-day simple moving average of $36.66 and a 200 day simple moving average of $36.97. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $81.18 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.01%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is 98.74%.

Analysts Set New Price Targets

A number of brokerages have commented on GSK. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.